January 28, 2025

FDA Approves Enhertu for Metastatic, HR-Positive, HER2-Low or -Ultralow Breast Cancer

Enhertu, a HER2-directed antibody-drug conjugate, was approved by the U.S. Food and Drug Administration for pretreated patients with metastatic HR-positive, HER2-low or HER2-ultralow breast cancer based on results from the DESTINY-Breast06 trial.

Conexiant

May 17, 2024

Depression, Stress Linked to Gut Health in Pregnancy

Researchers have found significant microbiome changes linked to maternal stress and depression.

Conexiant

May 28, 2024

HPV Vaccine Reduces Risk of Multiple Cancers, New Study

New research reveals the HPV vaccine significantly reduces the risk of multiple HPV-related cancers, particularly head and neck cancers in men, highlighting its crucial role in cancer prevention.

Conexiant

May 30, 2024

Study Links Abortion Bans to Increased Risk of Pregnancy Violence

Abortion restrictions are associated with higher rates of intimate partner violence during pregnancy.

Conexiant

August 27, 2024

Menopause Shifts Lipids, Cardiovascular Risk Rises

Perimenopausal women show a striking 213% increase in small-dense LDL particles, potentially explaining the post-menopause cardiovascular risk surge.

Conexiant

May 17, 2024

HPV Detection: Urine PCR vs. Cervical Smear

Concentrated urine PCR test proves nearly as effective as cervical smear in detecting HPV.

Conexiant

September 17, 2024

Trauma Exposure Linked to Accelerated Brain Aging, Alzheimer's Risk

Study reveals sexual trauma may accelerate white matter brain aging by over 3 years in women, potentially increasing Alzheimer's risk—a finding for health care providers addressing women's cognitive health.

Conexiant

April 29, 2024

Identifying Common Triggers of Photocontact Dermatitis

Discover how exposure to certain fruits, vegetables, drugs, and plants can trigger symptoms of photocontact dermatitis and the importance of seeking shade and wearing protective clothing in the sun.

Conexiant

December 30, 2024

Nutrafol Safety Signal Emerges in Case Study

A previously healthy 26-year-old developed severe liver injury after using Nutrafol, with a biopsy confirming marked necroinflammatory damage with complete resolution upon discontinuation.

Conexiant